Cardiovascular Toxicity and Immune Checkpoint Inhibitors

Cardiovascular Toxicity and Immune Checkpoint Inhibitors Guest: Joerg Herrmann, M.D. (@mayocvonc) Host: Malcolm R. Bell, M.D.  Immune checkpoints are integral to the immune system, ensuring that there is no overactivation once an immune response is triggered. Seven immune checkpoint inhibitors — which interfere with that natural brake in the immune system — are currently approved for use in cancer treatment. The immune checkpoint inhibitors unleash T cells to attack a tumor, with dramatic results. Joining us today to discuss immune checkpoint inhibitors and cardiovascular toxicity is Joerg Herrmann, M.D., director of the Cardio-Oncology Clinic at Mayo Clinic in Rochester, Minnesota. Specific topics discussed: Explanation and applications of immune checkpoint inhibitors Types of malignancies treated with T cell-based therapies and their outcomes Related cardiac toxicities and how to diagnose them Evaluation in the outpatient setting Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV. No CME credit offered for this episode. Podcast episode transcript found here.